-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Aug 9

PMID 30087850

Citations 7

Authors

Ajeet Gajra

Nagla Abdel Karim

Deborah A Mulford

Liza Cosca Villaruz

Marc Ryan Matrana

Haythem Y Ali

Edgardo S Santos

Tymara Berry

Teng Jin Ong

Alexandra Sanford

Katayoun Amiri

David R Spigel

Affiliations

Soon will be listed here.

Abstract

Introduction: The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified -paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2.

Methods: Chemotherapy-naive patients with stage IIIB/IV NSCLC and ECOG PS 2 received four cycles of -paclitaxel 100 mg/m days 1 and 8 plus carboplatin area under the curve 5 day 1 q3w (induction). Patients without progression received -paclitaxel monotherapy (100 mg/m days 1 and 8 q3w) until progression/unacceptable toxicity. Primary endpoint: percentage of patients discontinuing induction due to treatment-emergent adverse events (TEAEs).

Results: 11/40 treated patients (27.5%; 95% CI, 14.60-43.89) discontinued chemotherapy induction due to TEAEs; 16/40 (40.0%) continued -paclitaxel monotherapy. Median progression-free and overall survival were 4.4 (95% CI, 2.99-7.00) and 7.7 (95% CI, 4.93-13.17) months. Grade 3/4 TEAEs during induction included neutropenia (22.5%), anemia (17.5%), thrombocytopenia (5.0%), and peripheral neuropathy (2.5%).

Conclusion: This -paclitaxel-based regimen was tolerable in patients with advanced NSCLC and ECOG PS 2, with efficacy comparable to historical chemotherapy data.

Citing Articles

The role of DNA methylation and DNA methyltransferases (DNMTs) as potential biomarker and therapeutic target in non-small cell lung cancer (NSCLC).

Mohd Kamal K, Ghazali A, Ab Mutalib N, Abu N, Chua E, Masre S Heliyon. 2024; 10(19):e38663.

PMID: 39403460 PMC: 11472108. DOI: 10.1016/j.heliyon.2024.e38663.

Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426.

Ichikawa Y, Seki N, Honda T, Sakugawa M, Hosokawa S, Bessho A Transl Cancer Res. 2023; 12(4):873-886.

PMID: 37180670 PMC: 10175006. DOI: 10.21037/tcr-22-2144.

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas.

Tian Z, Yao W Front Oncol. 2022; 12:815900.

PMID: 35223497 PMC: 8866444. DOI: 10.3389/fonc.2022.815900.

First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.

Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Chiabudini M Cancer Med. 2021; 10(22):8127-8137.

PMID: 34668662 PMC: 8607256. DOI: 10.1002/cam4.4310.

Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease.

Gao G, Zhou C, Huang Y, Hong Z, Yu P, Chen Y Transl Lung Cancer Res. 2021; 10(6):2573-2587.

PMID: 34295663 PMC: 8264331. DOI: 10.21037/tlcr-21-371.

References

Kosmidis P, Dimopoulos M, Syrigos K, Nicolaides C, Aravantinos G, Boukovinas I . Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol. 2007; 2(2):135-40. View

Lilenbaum R, Samuels M, Wang X, Kong F, Janne P, Masters G . A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol. 2014; 10(1):143-7. PMC: 4320012. DOI: 10.1097/JTO.0000000000000347. View

Langer C, Li S, Schiller J, Tester W, Rapoport B, Johnson D . Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol. 2007; 25(4):418-23. DOI: 10.1200/JCO.2005.04.9452. View

Reynolds C, Barrera D, Jotte R, Spira A, Weissman C, Boehm K . Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2009; 4(12):1537-43. DOI: 10.1097/JTO.0b013e3181c0a2f4. View

Langer C, OByrne K, Socinski M, Mikhailov S, Lesniewski-Kmak K, Smakal M . Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3(6):623-30. DOI: 10.1097/JTO.0b013e3181753b4b. View

Morabito A, Gebbia V, Di Maio M, Cinieri S, Vigano M, Bianco R . Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer. 2013; 81(1):77-83. DOI: 10.1016/j.lungcan.2013.04.008. View

Gajra A, Jatoi A . Non–small-cell lung cancer in elderly patients: a discussion of treatment options. J Clin Oncol. 2014; 32(24):2562-9. DOI: 10.1200/JCO.2014.55.3099. View

Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A . Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010; 5(5):620-30. DOI: 10.1097/JTO.0b013e3181d2dcd9. View

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

10.

Lilenbaum R, Herndon 2nd J, List M, Desch C, Watson D, Miller A . Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2004; 23(1):190-6. DOI: 10.1200/JCO.2005.07.172. View

11.

Buccheri G, Ferrigno D, Tamburini M . Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996; 32A(7):1135-41. DOI: 10.1016/0959-8049(95)00664-8. View

12.

West H . Patients with advanced non-small-cell lung cancer and marginal performance status: walking the tight rope towards improved survival. J Clin Oncol. 2013; 31(23):2841-3. DOI: 10.1200/JCO.2013.50.1502. View

13.

Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D . Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol. 2008; 26(6):863-9. DOI: 10.1200/JCO.2007.13.2720. View

14.

Tabchi S, Kassouf E, Florescu M, Tehfe M, Blais N . Factors influencing treatment selection and survival in advanced lung cancer. Curr Oncol. 2017; 24(2):e115-e122. PMC: 5407874. DOI: 10.3747/co.24.3355. View

15.

Sweeney C, Zhu J, Sandler A, Schiller J, Belani C, Langer C . Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma . Cancer. 2001; 92(10):2639-47. DOI: 10.1002/1097-0142(20011115)92:10<2639::aid-cncr1617>3.0.co;2-8. View

16.

Socinski M, Bondarenko I, Karaseva N, Makhson A, Vynnychenko I, Okamoto I . Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012; 30(17):2055-62. DOI: 10.1200/JCO.2011.39.5848. View

17.

Lilenbaum R, Cashy J, Hensing T, Young S, Cella D . Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008; 3(2):125-9. DOI: 10.1097/JTO.0b013e3181622c17. View

18.

Zukin M, Barrios C, Pereira J, Ribeiro R, Beato C, do Nascimento Y . Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013; 31(23):2849-53. DOI: 10.1200/JCO.2012.48.1911. View